Main > ENDOCRINOLOGY > Diabetes Type II > Treatment > Co: FR. S. Lixisenatide

---

Co: FR. S. Lixisenatide's subsections
(*) Approved in BR; EU; IN. JP; MX
(*) USA Approval Date: 2016. 07.27.
Company
Licensor
Mechanism: GLP-1 Receptor Agonist
TradeMark (ex USA)
TradeMark (USA)
TradeMark (USA) Web-Site
UpDate: 2016. 07.28

Co: FR. S. Lixisenatide's products
This section has no products